The BCLAF1 (Bcl-2-associated transcription factor 1) antibody is a key tool for studying the multifunctional protein BCLAF1. which is implicated in transcriptional regulation, pre-mRNA splicing, apoptosis, and autophagy. BCLAF1 interacts with Bcl-2 family proteins to modulate apoptotic pathways and participates in DNA damage response by recruiting repair factors. It also serves as a scaffold for spliceosome components, influencing mRNA processing. Dysregulation of BCLAF1 has been linked to cancer progression, viral infections, and autoimmune diseases, making it a focus of biomedical research.
BCLAF1 antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunoprecipitation to detect protein expression, localization, and interactions. These antibodies help elucidate BCLAF1's nuclear-cytoplasmic shuttling dynamics and its role in stress responses. Commercial antibodies are often validated using BCLAF1 knockout cell lines to ensure specificity. Research highlights BCLAF1 overexpression in certain cancers (e.g., hepatocellular carcinoma, colorectal cancer), where it may promote tumorigenesis by suppressing apoptosis or enhancing genomic instability. Conversely, reduced BCLAF1 expression correlates with poor prognosis in other malignancies, suggesting context-dependent functions.
Additionally, BCLAF1 interacts with viral proteins (e.g., HSV-1 ICP27. HBV core protein), aiding viral replication or immune evasion. Its involvement in autoimmune disorders like systemic lupus erythematosus further underscores therapeutic relevance. BCLAF1 antibodies thus facilitate mechanistic studies and potential biomarker development for diverse diseases.